JPRN-UMIN000005317招募中未知
Effect of oral neurokinin-1 antagonist, aprepitant for chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving carboplatin/paclitaxel chemotherapy. - Effect of oral neurokinin-1 antagonist, aprepitant for chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving carboplatin/paclitaxel chemotherapy.
Department of gynecology, Fukuoka University Hospital0 个研究点目标入组 60 人开始时间: 2011年3月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patient has a serious hepatic insufficiency or renal failure 2) Patient has nausea or vomiting within 24 hours prior to chemotherapy 3) Patient has been treated with antiemetic agents within 48 hours prior to chemotherapy 4) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 5) Patient is unable to be administered dexamethasone for 3 days due to associated illnesses such as out-of-control diabetes mellitus 6) Patient is receiving pimozide 7) Patient is judged inappropriate by the investigator as subject for this study
研究者
相似试验
招募中
不适用
Study of oral neurokinin-1 antagonist, aprepitant for the prevention of nausea and vomiting in patients receiving chemotherapy with irinotecan alone or combination of irinotecan plus cisplatin for unresectable gastric cancergastric cancerJPRN-UMIN000004021Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine80
已完成
不适用
Study of efficacy and safety of oral neurokinin-1 antagonist, aprepitant for prevention of chemotherapy-induced nausea and vomiting associated with 5-FU/cisplatin chemotherapy in patients with head and neck cancer.head and neck cancerJPRN-UMIN000005071Department of otolaryngology , Nagasaki University Hospital20
招募中
2 期
Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies.hematologic malignanciesJPRN-UMIN000006690Kagoshima University Hospital, division of Hematology and Immunology40
招募中
不适用
Study of NK1-receptor antagonist; aprepitant for prevention of nausea and emesis in patients receiving chemotherapy with irinotecan for gastric cancer.Advanced gastric cancerJPRN-UMIN000011962Gastroenterologic Surgery, Kanazawa University55
已完成
3 期
Four drug anti-emetic studyCTRI/2021/04/032528CI AIIMS250